LUNG

Pulmonx Corporation (LUNG) | Rumor.io

Pulmonx

LUNG

Attention (50-day avg)0%

Attention rank (50-day avg)#3,738

Bullish sentiment (50-day avg)67%

Price to earnings ratio-1.48

Market capitalization82.8M

Earnings per share-1.15

Dividend yield (TTM)—

Revenue (annual)90.5M

Net income (annual)-54M

Social

What share of all stock conversation is about LUNG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 3

$LUNG is seeing significant volume, with the price potentially trending if it reaches $5.
The stock has been strong, with a recent price increase from $1.34 to $2.04, prompting some traders to hold or reenter the market.
Traders are watching for an opportunity to buy in, with some waiting for a pullback or a price above $2.25 to enter the market.

Generated by AI

Sentiment

Of the messages about LUNG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	87.5% +25.96	81.85% +3.18
Bearish	—	—	12.5% -25.96	18.15% -3.18

Bullish· Mar 6

$LUNG has shown significant momentum, surging by 27.95% to $2.06, breaking through the $1.78 resistance on 1.78M volume.
The company's Q4 earnings transcript has fueled the momentum, with a $2.79 target as a breakout confirmation.
The stock has decisively breached the $1.77 resistance on massive 3.95M volume, with a +25.46% surge to $2.02, signaling powerful momentum ignition.

Bearish· Oct 28

$LUNG's outdated Zephyr Valve technology has failed to gain traction since its FDA approval in 2018, despite competitors offering newer and more effective methods.
The company's reliance on a single product has led to significant cash burn and shareholder dilution, raising questions about its ability to scale and adapt to changing market conditions.
$LUNG's sales have not come close to meeting the company's touted market size, with slow adoption, niche use cases, and reimbursement hurdles contributing to ongoing losses and a lack of investor confidence.

Generated by AI

Topics

Of the messages about LUNG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	7.78%
Earnings	—	—	—	7.49%
Analysts	—	—	—	27.67%
Controversies	—	—	—	0%
Macro	—	—	—	27.38%
Technical Analysis	—	—	—	29.68%

Mar 6

$LUNG has broken out above $1.78 resistance on high volume, with a target of $2.79.
The stock's Q4 earnings transcript has provided a fundamental catalyst for the breakout, with multiple analysts flagging the stock before the move.
$LUNG has confirmed a powerful momentum surge, with a +30.43% move to $2.10 and a target of $2.89.

Generated by AI

Community

Of the messages about LUNG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	88.89%	33.97%
Newcomers	—	—	11.11%	66.03%

Regulars· Feb 23

LUNG, the ticker for Pulmonx Corporation, has seen a +13.5% gain.
Pulmonx Corporation has reported Q4 loss, but topped revenue estimates, and the company's financial results for 2022 have been released.
Canaccord Genuity has raised its price target for Pulmonx Corporation to $20, while Morgan Stanley has maintained an equal-weight rating and raised its price target to $11.

Newcomers· Mar 6

The asset LUNG has seen significant price movement, with a 29% increase since being flagged by analysts at $1.59.
The company's Q4 earnings have been cited as a key catalyst for the recent price surge, with many posts mentioning the potential for continued momentum.
The asset has broken through resistance levels, with posts highlighting the potential for further price increases, including targets of $2.89 and $283.92.

Generated by AI

News

Pulmonx Shares Fall Following Recent Gains

Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2.

26d agoYahoo Finance

Why is Pulmonx stock sliding today?

27d agoInvesting.com

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors

28d agoYahoo Finance

Also Discussed

Investors talking about LUNG also mention

#	Name	Attention
1	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
2	SILK - Silk Road Medical, Inc	——
3	LanzaTech Global Inc. Common StockLNZA	0%new
4	MKDWELL Tech Inc.MKDW	0%+0
5	Avanos Medical Inc.AVNS	0%0
6	Distribution Solutions Group, Inc.DSGR	0%0
7	Falcon's Beyond Global, Inc. Class A Common StockFBYD	0%new
8	OneConstruction Group Ltd.ONEG	0%0
9	AngioDynamics Inc.ANGO	0%new
10	Baird Medical Investment Holdings Ltd.BDMD	0%new

Pulmonx Corporation

Healthcare
Medical Devices

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for severe emphysema and other obstructive lung diseases. The company’s core offering is the Zephyr Endobronchial Valve, a bronchoscopic implant designed to reduce lung hyperinflation in patients who are not candidates for, or do not want, surgery. Pulmonx also provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which support patient evaluation, treatment planning, and clinical decision-making. Its products are used primarily by hospitals and specialty pulmonary centers within interventional pulmonology. Pulmonx serves a global clinical market and positions its portfolio around evidence-based tools that help physicians identify appropriate patients and deliver targeted lung-volume reduction therapy.

Website

Location

700 Chesapeake Drive

Redwood City, CA, 94063

United States

Social

What share of all stock conversation is about LUNG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 3

$LUNG is seeing significant volume, with the price potentially trending if it reaches $5.
The stock has been strong, with a recent price increase from $1.34 to $2.04, prompting some traders to hold or reenter the market.
Traders are watching for an opportunity to buy in, with some waiting for a pullback or a price above $2.25 to enter the market.

Generated by AI

Sentiment

Of the messages about LUNG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	87.5% +25.96	81.85% +3.18
Bearish	—	—	12.5% -25.96	18.15% -3.18

Bullish· Mar 6

$LUNG has shown significant momentum, surging by 27.95% to $2.06, breaking through the $1.78 resistance on 1.78M volume.
The company's Q4 earnings transcript has fueled the momentum, with a $2.79 target as a breakout confirmation.
The stock has decisively breached the $1.77 resistance on massive 3.95M volume, with a +25.46% surge to $2.02, signaling powerful momentum ignition.

Bearish· Oct 28

$LUNG's outdated Zephyr Valve technology has failed to gain traction since its FDA approval in 2018, despite competitors offering newer and more effective methods.
The company's reliance on a single product has led to significant cash burn and shareholder dilution, raising questions about its ability to scale and adapt to changing market conditions.
$LUNG's sales have not come close to meeting the company's touted market size, with slow adoption, niche use cases, and reimbursement hurdles contributing to ongoing losses and a lack of investor confidence.

Generated by AI

Topics

Of the messages about LUNG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	7.78%
Earnings	—	—	—	7.49%
Analysts	—	—	—	27.67%
Controversies	—	—	—	0%
Macro	—	—	—	27.38%
Technical Analysis	—	—	—	29.68%

Mar 6

$LUNG has broken out above $1.78 resistance on high volume, with a target of $2.79.
The stock's Q4 earnings transcript has provided a fundamental catalyst for the breakout, with multiple analysts flagging the stock before the move.
$LUNG has confirmed a powerful momentum surge, with a +30.43% move to $2.10 and a target of $2.89.

Generated by AI

Community

Of the messages about LUNG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	88.89%	33.97%
Newcomers	—	—	11.11%	66.03%

Regulars· Feb 23

LUNG, the ticker for Pulmonx Corporation, has seen a +13.5% gain.
Pulmonx Corporation has reported Q4 loss, but topped revenue estimates, and the company's financial results for 2022 have been released.
Canaccord Genuity has raised its price target for Pulmonx Corporation to $20, while Morgan Stanley has maintained an equal-weight rating and raised its price target to $11.

Newcomers· Mar 6

The asset LUNG has seen significant price movement, with a 29% increase since being flagged by analysts at $1.59.
The company's Q4 earnings have been cited as a key catalyst for the recent price surge, with many posts mentioning the potential for continued momentum.
The asset has broken through resistance levels, with posts highlighting the potential for further price increases, including targets of $2.89 and $283.92.

Generated by AI

Pulmonx

Social

Aug 3

Bullish· Mar 6

Bearish· Oct 28

Mar 6

Regulars· Feb 23

Newcomers· Mar 6

Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares

Pulmonx general counsel David Lehman sells $32,393 in stock

Pulmonx chief science officer sells $32,192 in stock

Pulmonx Shares Fall Following Recent Gains

Why is Pulmonx stock sliding today?

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Pulmonx Corporation

Company Information

Location

Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares

Pulmonx general counsel David Lehman sells $32,393 in stock

Pulmonx chief science officer sells $32,192 in stock

Pulmonx Shares Fall Following Recent Gains

Why is Pulmonx stock sliding today?

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Aug 3

Bullish· Mar 6

Bearish· Oct 28

Mar 6

Regulars· Feb 23

Newcomers· Mar 6